# DPX-Survivac and Checkpoint Inhibitor in DLBCL

> **NCT03349450** · PHASE2 · COMPLETED · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 25 (actual)

## Conditions studied

- Adult Diffuse Large Cell Lymphoma
- Recurrent
- Adult Refractory Diffuse Large B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** DPX-Survivac
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Cyclophosphamide 50mg

## Key facts

- **NCT ID:** NCT03349450
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-13
- **Primary completion:** 2021-10-31
- **Final completion:** 2023-07-18
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03349450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03349450, "DPX-Survivac and Checkpoint Inhibitor in DLBCL". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03349450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*